PF-05190457   Click here for help

GtoPdb Ligand ID: 9060

Synonyms: PF-5190457
PDB Ligand
Compound class: Synthetic organic
Comment: PF-05190457 is a selective, orally bioavailable and competitive antagonist of the ghrelin receptor [1], with potential therapeutic utility for the treatment of obesity and type 2 diabetes [2], and for treating alcohol use disorder.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 5
Topological polar surface area 94.87
Molecular weight 512.24
XLogP 2.94
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Cc1ncnc(c1)c1ccc2c(c1)CCC2N1CC2(C1)CCN(CC2)C(=O)Cc1nc2n(c1)cc(s2)C
Isomeric SMILES Cc1ncnc(c1)c1ccc2c(c1)CC[C@H]2N1CC2(C1)CCN(CC2)C(=O)Cc1nc2n(c1)cc(s2)C
InChI InChI=1S/C29H32N6OS/c1-19-11-25(31-18-30-19)22-3-5-24-21(12-22)4-6-26(24)35-16-29(17-35)7-9-33(10-8-29)27(36)13-23-15-34-14-20(2)37-28(34)32-23/h3,5,11-12,14-15,18,26H,4,6-10,13,16-17H2,1-2H3/t26-/m1/s1
InChI Key ZIUDADZJCKGWKR-AREMUKBSSA-N
References
1. Bhattacharya SK, Andrews K, Beveridge R, Cameron KO, Chen C, Dunn M, Fernando D, Gao H, Hepworth D, Jackson VM et al.. (2014)
Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate.
ACS Med Chem Lett, 5 (5): 474-9. [PMID:24900864]
2. Kong J, Chuddy J, Stock IA, Loria PM, Straub SV, Vage C, Cameron KO, Bhattacharya SK, Lapham K, McClure KF et al.. (2016)
Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo.
Br J Pharmacol, 173 (9): 1452-64. [PMID:26784385]